Stocks · News reference
BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $109 to $111.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Liquidia's stock fell 20% week-to-date following its Q2 earnings report, despite beating revenue expectations ($171.7M vs. $171M consensus) and posting a $74.7M net profit. The decline was attributed to the stock's steep 155% year-to-date run-up creating unrealistic expectations. The company's pulmonary hypertension drug Yutrepia is performing well, though concerns remain about its reliance on a single molecule.
Read original at the-motley-foolWells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raises the price target from $62 to $108.
Read original at benzingaTop analysts changed outlook on top names. Truist, Morgan Stanley, B of A Securities, HC Wainwright, Baird, and Stephens & Co. altered price targets for various stocks.
Read original at benzingaB of A Securities analyst Jason Gerberry maintains Liquidia (NASDAQ:LQDA) with a Neutral and raises the price target from $79 to $92.
Read original at benzinga